← Leaderboards
Myles S Wolf
Duke University
$18,390,362
Attributed
$19,916,542
Total exposure
16
Grants
15
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $2M · FY2005–25$2.5M$1.9M$1.3M$625K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$19,916,542 · 16
By mechanism
R01$10,819,387 · 4
UH3$5,427,044 · 1
U01$1,031,520 · 1
UG3$842,040 · 1
K24$803,404 · 1
K23$649,595 · 1
Top collaborators
- Michel Benjamin Chonchol5 shared
- Berenice Yolande Gitomer5 shared
Most similar at Duke University
Same institution · by research overlap
- Pei Zhou$18,119,545
- William J Steinbach$15,812,111
- Henry F Chambers$93,384,193
- Kenneth D Poss$25,540,868
- Christian R Raetz$13,955,306
Others in their field
Top investigators on “Inorganic Phosphate”
- Clark Algaier · Midwest Research Institute$31,674,880
- Robert J Hamers · University Of Wisconsin-Madison$19,800,000
- Stewart H Shuman · Sloan-Kettering Institute For Cancer Res$18,902,943
- Robert G Weiss · Johns Hopkins University$13,669,572
- Isidro B. Benjamin Salusky · University Of California Los Angeles$13,363,669
- Steven M Hersch · Emory University$10,959,381
Research focus
Inorganic PhosphateCardiovascular DiseasesSerumMineralsFibroblast Growth Factor 23Cessation Of LifeChronic Kidney FailureMetabolismAffectCardiovascular Disorder RiskKidneyCohortHormonesCohort StudiesRisk FactorsResponseMortality Vital StatisticsIntakeFutureDesignLinkBaseEnd Stage Renal FailureStaging
Grant awards (54)
Tissue-Specific Regulation and Effects of CYP24A1$417,559
R01 · FY2025 · DK · contact PI
Tissue-Specific Regulation and Effects of CYP24A1$515,363
R01 · FY2024 · DK · contact PI
Tissue-Specific Regulation and Effects of CYP24A1$547,463
R01 · FY2023 · DK · contact PI
HiLo$1,298,334
UH3 · FY2022 · DK · contact PI
HiLo$1,327,995
UH3 · FY2021 · DK · contact PI
HiLo$1,356,495
UH3 · FY2020 · DK · contact PI
HiLo$1,444,220
UH3 · FY2019 · DK · contact PI
HiLo$842,040
UG3 · FY2018 · DK · contact PI
FGF23 and Cardiovascular Disease in CKD$384,752
R01 · FY2016 · DK · contact PI
FGF-23 and clinical outcomes in ADPKD patients$344,584
R01 · FY2016 · DK
Role of FGF23 in Mineral Metabolism Across the Spectrum of Chronic Kidney Disease$238,500
R01 · FY2016 · DK · contact PI
Role of FGF23 in Mineral Metabolism Across the Spectrum of Chronic Kidney Disease$231,750
R01 · FY2016 · DK · contact PI
Mentored Patient Oriented Research in Mineral Metabolism$156,508
K24 · FY2016 · DK · contact PI
FGF23 and Cardiovascular Disease in CKD$544,649
R01 · FY2015 · DK · contact PI
FGF-23 and clinical outcomes in ADPKD patients$479,326
R01 · FY2015 · DK
Pilot Studies Targeting Mineral Metabolism in Chronic Kidney Disease$343,840
U01 · FY2015 · DK · contact PI
Role of FGF23 in Mineral Metabolism Across the Spectrum of Chronic Kidney Disease$224,938
R01 · FY2015 · DK · contact PI
Mentored Patient Oriented Research in Mineral Metabolism$160,407
K24 · FY2015 · DK · contact PI
FGF23 and Cardiovascular Disease in CKD$592,099
R01 · FY2014 · DK · contact PI
FGF-23 and clinical outcomes in ADPKD patients$485,928
R01 · FY2014 · DK
Pilot Studies Targeting Mineral Metabolism in Chronic Kidney Disease$343,840
U01 · FY2014 · DK · contact PI
FGF23 and mineral metabolism in Acute Kidney Injury$260,565
R21 · FY2014 · DK · contact PI
Role of FGF23 in Mineral Metabolism Across the Spectrum of Chronic Kidney Disease$198,560
R01 · FY2014 · DK · contact PI
Mentored Patient Oriented Research in Mineral Metabolism$161,515
K24 · FY2014 · DK · contact PI
FGF23 and Cardiovascular Disease in CKD$564,346
R01 · FY2013 · DK · contact PI
FGF-23 and clinical outcomes in ADPKD patients$454,586
R01 · FY2013 · DK
Pilot Studies Targeting Mineral Metabolism in CKD$343,840
U01 · FY2013 · DK · contact PI
Role of FGF23 in Mineral Metabolism Across the Spectrum of Chronic Kidney Disease$212,185
R01 · FY2013 · DK · contact PI
Mentored Patient Oriented Research in Mineral Metabolism$161,515
K24 · FY2013 · DK · contact PI
FGF23 and Cardiovascular Disease in CKD$8,783
R01 · FY2013 · DK · contact PI
FGF23 and Cardiovascular Disease in CKD$561,038
R01 · FY2012 · DK · contact PI
FGF-23 and clinical outcomes in ADPKD patients$524,846
R01 · FY2012 · DK
Mentored Patient Oriented Research in Mineral Metabolism$163,459
K24 · FY2012 · DK · contact PI
FGF23 and Cardiovascular Disease in CKD$464,978
R01 · FY2011 · DK · contact PI
Role of FGF-23 in Mineral Metabolism Across the Spectum of Chronic Kidney Disease$354,664
R01 · FY2011 · DK · contact PI
FGF23 and Cardiovascular Disease in CKD$62,912
R01 · FY2011 · DK · contact PI
Role of FGF-23 in Mineral Metabolism Across the Spectum of Chronic Kidney Disease$358,246
R01 · FY2010 · DK · contact PI
FGF23 and Cardiovascular Disease in CKD$324,253
R01 · FY2010 · DK · contact PI
Role of FGF-23 in Mineral Metabolism Across the Spectum of Chronic Kidney Disease$361,865
R01 · FY2009 · DK · contact PI
FGF23 and Cardiovascular Disease in CKD$327,458
R01 · FY2009 · DK · contact PI
Role of FGF-23 in Mineral Metabolism Across the Spectum of Chronic Kidney Disease$361,865
R01 · FY2008 · DK · contact PI
FGF23 and Cardiovascular Disease in CKD$340,641
R01 · FY2008 · DK · contact PI
PHOSPHATE, VITAMIN D AND CARDIOVASCULAR DISEASE IN CHRONIC KIDNEY DISEASE$23,959
M01 · FY2008 · RR · contact PI
REDUCED PHOSPHATE INTAKE IN "NORMO-PHOSPHATEMIC" CHRONIC KIDNEY DISEASE PATIENTS$10,361
M01 · FY2008 · RR · contact PI
REDUCED PHOSPHATE INTAKE IN NORMO-PHOSPHATEMIC CHRONIC KIDNEY DISEASE PATIENTS$324
M01 · FY2008 · RR · contact PI
Role of FGF-23 in Mineral Metabolism Across the Spectum of Chronic Kidney Disease$331,250
R01 · FY2007 · DK · contact PI
Cardiovascular Disease Following Hypertensive Pregnancy$129,951
K23 · FY2007 · RR · contact PI
REDUCED PHOSPHATE INTAKE IN "NORMO-PHOSPHATEMIC" CHRONIC KIDNEY DISEASE PATIENTS$23,147
M01 · FY2007 · RR · contact PI
REDUCED PHOSPHATE INTAKE IN NORMO-PHOSPHATEMIC CHRONIC KIDNEY DISEASE PATIENTS$964
M01 · FY2007 · RR · contact PI
Cardiovascular Disease Following Hypertensive Pregnancy$129,791
K23 · FY2006 · RR · contact PI
REDUCED PHOSPHATE INTAKE IN "NORMO-PHOSPHATEMIC" CHRONIC KIDNEY DISEASE PATIENTS$24,232
M01 · FY2006 · RR · contact PI
Cardiovascular Disease Following Hypertensive Pregnancy$129,951
K23 · FY2005 · RR
Cardiovascular Disease Following Hypertensive Pregnancy$129,951
K23 · FY2004 · RR
Cardiovascular Disease Following Hypertensive Pregnancy$129,951
K23 · FY2003 · RR